Amyotrophic Lateral Sclerosis (ALS)
ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the United States and an estimated 450,000 people worldwide. ALS causes the progressive degeneration of motor neurons, resulting in rapidly advancing muscle weakness and atrophy that eventually leads to partial or total paralysis and death. The disease is fatal within just four years on average.
In recent years, ALS has come to the forefront of public knowledge with "The Ice Bucket Challenge", started by Boston athlete Pete Frates and the recent death of Stephen Hawking, who suffered the effects of the disease for nearly 55 years.
Bach Pharma's GVT®, has high potential for the TREATMENT of ALS. Currently, there are only two drugs approved in the U.S. and neither cure, nor effectively treat ALS, they only slow the progression while still give the patient many different side effects.
ALS is a debilitating fatal disease and patients have few options for treatment. Development of GVT® in this area may provide a significant benefit to ALS patients.